CLINICAL PR

BOOTS IRELAND ANNOUNCES PARTNERSHIP WITH THE HYGIENE BANK IRELAND

Boots Ireland has announced a new partnership with The Hygiene Bank Ireland, providing drop off points in ten stores where people can donate hygiene products which are provided to those in need. People are invited to donate a range of unopened and unused products such as dental products, deodorants, body wash, nappies, baby wipes, razors and shaving foam, period products, hairbrushes, shampoo and conditioner. This new partnership was announced ahead of National Hygiene Week, from 12 – 18th September 2022, which aims to raise awareness about hygiene poverty and its impact on those who are affected.

Hygiene poverty is not being able to afford many of the everyday hygiene and personal grooming products most of us take for granted. The reality of low income is that it restricts people’s options, leaving people caught between being able to heat homes, pay rent, eat or be clean. The Hygiene Bank Ireland is a grassroots organisation, which tackles hygiene poverty by delivering donated hygiene and household cleaning products to community partners who work with vulnerable and marginalised communities. Initially Boots Ireland will be operating ten drop-off points around the country, and everyone is invited to donate products if they are able to do so. The stores in the initial phase include five locations in Dublin – Dundrum, Carrickmines, Swords, Liffey Valley and Blanchardstown, Letterkenny Retail Park, Letterkenny, two locations in Cork – Blackpool and Half Moon Street – as well as Shop Street, Galway and Abbey St., Wicklow Town.

Speaking at the launch of the new partnership, Ciára Dalton, Head of Marketing, The Hygiene Bank Ireland said, “Everyone has the right to an adequate standard of living, yet with 640,000 people at risk of poverty and the cost of living on the rise, hygiene products can often be at the bottom of the shopping list for people who are struggling to make ends meet. The impact of this can be immense. As the national charity for hygiene poverty, The Hygiene Bank Ireland is dedicated to working towards eradicating this problem whilst supporting those most at-risk of hygiene poverty with the products they need.”

CALLS TO SCRAP VAT ON DEFIBRILLATORS

The VAT on defibrillators is a “tax on saving lives” and must be scrapped, the Irish Heart Foundation insisted in its preBudget submission recently. The charity claims the average cost of an automated external defibrillator (AED) - ¤1,500 including ¤345 VAT - makes them unaffordable for many community organisations. It wants Minister for Finance, Paschal Donohoe, to remove the 23% tax burden levied on the portable, computerised devices in next month’s Budget. The Foundation’s Resuscitation Manager, Brigid Sinnott, said sporting and voluntary groups are also being hit with an estimated extra ¤100 in VAT when they replace pads and batteries – required regularly to keep the AEDs in working order. “The VAT on defibrillators is a tax on saving lives and it’s time it was removed,” said Ms Sinnott, who is also a community first responder trained to administer defibrillation before paramedics arrive. “The more AEDs there are available in local communities and accessible to the public, the more lives can be saved.”

In some cardiac arrests, AEDs deliver a shock to the heart to resume its normal rhythm. More than 8,400 people so far have signed an online petition launched by the charity as part of its drive to have the VAT on AEDs scrapped. “We hope the Minister will have listened to the thousands of individuals who have supported our petition by the time he delivers his Budget,” Ms Sinnott added. Volunteer group Community First Responders Ireland (CFR Ireland) is also backing the call. To sign the AED petition, visit: https://my.uplift.ie/petitions/ scrap-vat-on-aeds-it-s-a-tax-onsaving-lives.

CHRONIC PAIN IRELAND MARKS 30TH ANNIVERSARY WITH EVENTS TO PROVIDE ADVICE AND RESPITE

Chronic Pain Ireland (CPI), an organisation dedicated to supporting people living with chronic pain and their families, is to mark the 30th anniversary of its foundation by hosting a series of events for Pain Awareness Month, which starts today (September 1st). The World Health Assembly (WHA) – a subsection of the World Health Organization (WHO) – has declared September Pain Awareness Month. The event is designed to bring patients and advocacy groups from around the world together to highlight the condition of chronic pain. CPI, in conjunction with the HSE, is supporting its members throughout Pain Awareness Month via its Living Well with Chronic Pain selfmanagement programmes. These seven-week online programmes are available for free and are designed

Boots Hygiene Bank Letterkenny, Martha Ryan, Vic Riley, Margaret McFadden, Carla Harkin Resuscitation Manager with the Irish Heart Foundation Brigid Sinnott with Community First Responders Ireland chairperson John Fitzgerald

Chair of Chronic Pain Ireland Martha Phelan

to support those living with chronic pain conditions to self-manage by providing them with tools, techniques and coping strategies. CPI and the HSE are also working together to offer specific programmes for those aged 18-30. Top university researchers who engage with CPI through its patient and public involvement (PPI) partnerships will also be on hand to provide insights on their studies into chronic pain. Also part of CPI’s 30-year milestone celebrations is the launch of the Hidden Disabilities Sunflower initiative to highlight the plight of those living with chronic pain and non-visible disabilities. Sunflower lanyards are being gifted to all CPI members from today and can be worn in public to discreetly indicate to others that the wearer has a hidden disability and may require additional support. Chronic pain is classified as pain that persists beyond the time of healing, typically around three months. While many people suffer chronic pain due to injury or illness, others can experience pain in the absence of any obvious cause. According to figures released by Irish Pain Society, Ireland has just 27 dedicated pain consultants operating across the public system, meaning that 41% of patients are currently waiting more than 12 months for their first appointment with a chronic pain specialist, while 18% are waiting the same length of time for their first treatment.

The Irish Pain Society’s figures estimate that chronic pain costs the Irish economy around ¤4.7billion per year, more than 2.5% of GDP. Among those with chronic pain, 29% cannot work because of their condition, while 42% said they think others doubt the existence of their pain. Some 21% said their pain was so intense that they wanted to die.

OVER-50S URGED TO ‘UNDERSTAND SHINGLES’

Broadcaster Teresa Mannion has called on the over-50s in Ireland to speak with their doctor, practice nurse or pharmacist about the risk factors for shingles and shingles prevention. New research conducted on behalf of GSK shows that almost one-fifth of respondents (19%) over-50 reported that they had experienced shingles and over half (55%) of those surveyed said they knew someone who was affected by it. The GSK ‘Understanding Shingles’ research1 looked at awareness levels, knowledge and perceptions of shingles among the over-50s in Ireland. Ms Mannion made the appeal because despite over half of respondents (56%) perceiving shingles to be a serious disease, a considerable number of respondents - 43% - said they felt it was unlikely that they would develop shingles over the next year. Ms Mannion also urged the over50s to find out about the risk factors as one-in-three people who have had chickenpox are at risk of developing shingles in their lifetime.2, 3 While most people make a full recovery, shingles can potentially lead to serious and long-lasting complications. Post-herpetic neuralgia (PHN) is the most common complication, a prolonged nerve pain in the area affected by shingles that can last for months or even longer.4 PHN occurs in around 20% of all shingles cases, with the over-50s particularly at risk.5 The survey shows that 57% of respondents said they were extremely or somewhat knowledgeable about shingles and reveals good awareness of many of the main symptoms - including a red rash (76%), pain, burning, numbness or tingling in one part of the body (71%) and itching (55%). It also demonstrates that some of the main risk factors associated with shingles are well understood, with recognition of a weakened immune system (62%), being under stress (48%) and agerelated declining immunity (47%). Additionally, 42% felt that shingles had an ‘extremely negative’ impact on quality of life. Commenting on the research findings, Ms Mannion said: “I can speak from personal experience as I developed shingles and it really stopped me in my tracks. It can be a severely painful, debilitating condition, and it impacted my personal and professional life, so it is not to be taken lightly. I’m heartened to see that over half of the respondents believe shingles is a serious condition, but I’m also concerned that many of the over 50s don’t feel that they are at risk. As shingles has a broad range of risk factors, I’d advise anyone in that age group to contact their doctor, practice nurse or pharmacist to discuss options.” Chair of Chronic Pain Ireland, Martina Phelan, added: “Shingles can be very painful. This pain is described as burning, shooting, stabbing or even constant unbearable itching. It does not happen to everyone, and it may only last for a few weeks, but some people can experience postherpetic neuralgia (PHN), a chronic condition that is difficult to treat and may cause pain for months, or longer. People don’t know as much as we’d like about shingles and there are many misconceptions. We are pleased to be part of the Understanding Shingles campaign as we find shingles is not always taken as seriously as it should be.” Visit www.understandingshingles.ie to learn more about shingles.

RHYTHM PHARMACEUTICALS ANNOUNCES IMCIVREE® (SETMELANOTIDE) GRANTED MARKETING AUTHORIZATION BY EUROPEAN COMMISSION FOR TREATMENT OF OBESITY AND CONTROL OF HUNGER IN BARDET-BIEDL SYNDROME

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercialstage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, has announced that the European Commission (EC) has expanded the marketing authorization for IMCIVREE® (setmelanotide) to include the treatment of obesity and control of hunger associated with genetically confirmed Bardet-Biedl syndrome (BBS) in adult and pediatric patients 6 years of age and older. “Patients and families have long endured a significant need for a therapy to address the burdens of hyperphagia and severe obesity often associated with BBS,” said Philip Beales, M.D., University College London, UCL Great Ormond Street Institute of Child Health. “Having new treatment options available can help address the physical and emotional aspects of this devastating disease, offering patients and their families relief and improved quality of life.” BBS is a rare genetic disease that affects approximately 2,500 people in the European Union (EU) and United Kingdom (UK). People living with BBS may experience insatiable hunger, also known as hyperphagia, and severe obesity beginning early in life. Approximately 1,500 patients have been diagnosed with BBS and are now being cared for at academic settings in the EU and UK. Under the terms of the Revenue Interest Financing Agreement with HealthCare Royalty Partners announced on June 16, 2022, Rhythm is now eligible to receive an additional investment of $37.5 million following EC marketing authorization for setmelanotide for BBS. Rhythm had received an initial investment amount of $37.5 million from HealthCare Royalty as a result of the approval of setmelanotide by the U.S. Food and Drug Administration (FDA), and the Company remains eligible for an additional investment amount of $25 million, which would be payable upon the achievement of certain agreed sales milestones in 2023.

Priority Review Status Granted for New Drug Submission for Setmelanotide in Canada

Rhythm also announced today that Health Canada has granted Priority Review for Rhythm’s New Drug Submission for setmelanotide, indicated in adult and pediatric patients 6 years of age and older with impairments in the MC4R pathway due to genetic diseases, for the treatment of obesity and control of hunger in BBS or biallelic pro-opiomelanocortin (POMC), proprotein convertase subtilisin/ kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency. Priority Review shortens Health Canada’s submission review performance target to 180 days, in comparison to 300 days for non-priority review. Priority Review may be granted for drug submissions in Canada for a serious, life-threatening or severely debilitating disease or condition for which there is substantial evidence of clinical effectiveness that the drug provides effective treatment, prevention or diagnosis of a disease or condition for which no drug is presently marketed in Canada or a significant increase in efficacy and/or significant decrease in risk such that the overall benefit/risk profile is improved over existing therapies, preventatives or diagnostic agents for a disease or condition that is not adequately managed by a drug marketed in Canada.

“These two important regulatory milestones underscore the global unmet need to treat the hyperphagia and severe obesity associated with these rare MC4R pathway diseases,” said David Meeker, M.D., Chairman, President and Chief Executive Officer of Rhythm. “We are working closely with Health Technology Assessment bodies and payers throughout the EU on a country-by-country basis to achieve market access and reimbursement in order to make IMCIVREE available to eligible patients as rapidly as possible. Taken together with the recent FDA approval for BBS in June, we are making significant advances in our mission of delivering the first precision medicine for MC4R pathway diseases to patients across the world.”

ACCORD HEALTHCARE LAUNCH ABIRATERONE ACCORD 250MG FILM-COATED TABLETS

Accord Healthcare Launch Abiraterone Accord 500mg FilmCoated Tablets

Accord Healthcare is delighted to announce the launch of another medicine to their already extensive high-tech portfolio: Abiraterone Accord 500 mg filmcoated tablets which comes in a pack of 56 tablets. Abiraterone Accord is indicated with prednisone or prednisolone for: • the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT). • the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. • the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen. Please refer to the Summary of Product Characteristics (SPC) for further information. The SPC will be available from the launch date at www.hpra.ie and for Healthcare Professionals at www.accordhealthcare.ie.

Abiraterone Accord 250 mg filmcoated tablets will be available from both full line wholesalers from launch. For further information please contact Accord in Cork on 021 461 9040 or visit www.accord-healthcare.ie

Think High-Techs, Think Accord ASTELLAS’ EVRENZO™

(ROXADUSTAT) TO BE REIMBURSED UNDER THE HIGH TECH DRUGS SCHEME IN IRELAND FOR ADULTS WITH SYMPTOMATIC ANAEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD)

Astellas Pharma Company Ltd. (part of the Astellas Pharma Inc group TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) is pleased to announce that EVRENZO™ (roxadustat) has been granted reimbursement, in line with its marketing authorisation under the High Tech Drugs Scheme in Ireland from 1st September, 2022, as an option for treating adult patients with symptomatic anaemia associated with CKD. Roxadustat is the first and only HIF-PH inhibitor licensed and reimbursed for use in Ireland. The licence was based on results from a comprehensive pivotal Phase 3 programme comprising of eight multicentre and randomised studies, which involved 9,600 patients worldwide.6-11 The results of this programme support roxadustat as efficacious in achieving and maintaining target haemoglobin (Hb) levels (10–12 g/ dL) in patients with symptomatic anaemia of CKD regardless of dialysis status and irrespective of prior erythropoiesis-stimulating agent (ESA) treatment.6-10 The safety profile observed in the roxadustat development programme is reflective of the CKD populations studied and comparable to ESAs.6-11 ‘This is an excellent demonstration of how a ground-breaking, Nobel Prize winning, scientific discovery can inform and pave the way for innovative medicines that can benefit patients.’ said Dr. Timir Patel, Medical Director, Astellas UK and Ireland. ‘Through its novel mechanism of action, roxadustat offers physicians an orally administered option to tackle anaemia of CKD, a complex and multi-faceted disease that can be hugely debilitating.’ Roxadustat activates the body’s natural response to reduced oxygen levels in the blood via inhibition of the HIF-PH pathway. The response involves the regulation of multiple, coordinated processes that improve iron absorption and mobilisation, and increase red cell production, and can therefore assist in the management of anaemia of CKD. According to The WHO, around 20% of people living with diagnosed CKD suffer from anaemia.3,4 Anaemia of CKD symptoms include dizziness, fatigue and headaches, and can be associated with significant impairment in quality of life.12-15 Additionally, patients with CKD that also suffer from anaemia have impaired health-related quality of life compared to patients without the added complication of anaemia.5

‘Chronic kidney disease patients suffer frequently from anaemia and this complication of CKD has greater impact as CKD worsens. Anaemia significantly impacts patient’s quality of life and vitality’, said Prof. Donal Reddan, Consultant Nephrologist, Galway University Hospital. ‘This licence enhances patient care by providing a novel alternative option for managing anaemia and improving patient’s quality of life’.

PATIENT GROUP CALLS FOR EXPANDED ACCESS TO MEDICAL CANNABIS ON ‘NATIONAL DAY OF ACTION’

A leading patient advocacy group has called for a major overhaul of Ireland’s cannabis laws on the day that campaigners rally outside the Department of Health. The Patients For Safe Access (PFSA) group said little progress has been made since the Medical Cannabis Access Programme (MCAP) was introduced here, and they insisted that more action is needed immediately. PFSA organised a large-scale event outside the Department of Health’s offices in Dublin where speakers called for changes to be made to expand access to medical cannabis.

Speakers at the event included Martin O’Brien and Alicia Maher of PFSA, Deputy Gino Kenny, Peter Reynolds of the Cannabis Industry Council and the activist Martin Condon.

Martin O’Brien, the PFSA director, said that until major changes are made to Ireland’s drugs, barriers to access would continue to inflict real suffering on patients, some of whom are emigrating to escape needless constraints.

“Many patients and those who care about this issue hoped that the limited MCAP reforms would represent a new dawn. Unfortunately, three years on, it has become abundantly clear that the existing law is not fit for purpose. “People with a range of serious medical conditions are not able to access cannabis legally. In spite of the evidence showing the benefits of cannabis in treating the chronic pain which so many people suffer from, the Government has slammed the door shut.

“Under MCAP, patients have to exhaust several other medical avenues before being allowed onto it, but we firmly believe that the Programme should be open to any patient with a condition that can be treated with medical cannabis,” O’Brien said.

Another leading voice within PFSA is Alicia Maher, a PhD candidate in the University of Limerick who left Ireland in 2019 to move to Spain, where she can legally access cannabis to cope with chronic pain. “Nobody should have to struggle to get the medicine they need, but for the many Irish people who require medical cannabis, that is the reality. And for more than a few people, that entails travelling back and forth between countries, bringing sick relatives on journeys they should not have to make, or in my case, having to leave my family just to be able to get by. This has to end,” Maher said.

LATE-BREAKING DUPIXENT® (DUPILUMAB) DATA AT ERS 2022 SHOW CONSISTENT EFFICACY AND SAFETY PROFILE FOR UP TO TWO YEARS IN CHILDREN AGED 6 TO 11 YEARS WITH MODERATE-TO-SEVERE ASTHMA

Results from a Phase 3 openlabel extension trial demonstrated the efficacy and safety profile of Dupixent® (dupilumab) as a maintenance therapy when added to other asthma medications was consistent for up to two years in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma with evidence of type 2 inflammation. These results were presented today in a late-breaking session at the 2022 European Respiratory Society (ERS) International Congress, which coincides with the milestone that more than 500,000 people around the world have been treated with Dupixent in its approved indications. Professor of Pediatrics, Director of the Center for Pediatric Asthma Research, Monroe Carell Jr. Children’s Hospital, Vanderbilt University Medical Center “Children with uncontrolled moderate-to-severe asthma may experience long-term persistent coughing, difficulty breathing, unpredictable asthma attacks and impaired lung function, which can lead to complications later in life as they grow and develop. An established safety profile balanced with efficacy is always a priority when treating children with a chronic disease, such as those with uncontrolled moderate-to-severe asthma with an eosinophilic phenotype or oral corticosteroid dependent asthma. These new data further support the consistent safety profile of longterm Dupixent - which is indicated for the treatment of uncontrolled moderate to severe asthma with an eosinophilic phenotype or oral corticosteroid dependent asthma - and its ability to provide sustained improvements in lung function and reductions in asthma exacerbations in children as young as 6 years old.” The results are from data in children who entered the extension trial after finishing active treatment or placebo in the Phase 3 trial (pivotal trial). Children in the extension trial were treated for up to an additional year with Dupixent, providing up to two years of data

in total. Children treated with Dupixent in the extension trial experienced a: • Low rate of severe asthma attacks with an average of 0.118-0.124 events per year, compared to 2.16-2.56 events per year at baseline in the pivotal trial. • Sustained improvement in lung function at 52 weeks of 9.43-12.6 percentage points from baseline in the pivotal trial, measured by percent predicted

FEV1 (FEV1pp). FEV1pp seeks to evaluate a patient’s change in lung function compared to their predicted lung function based on age, height, sex and ethnicity to account for children’s growing lung capacity at different stages of development. o Children who switched from placebo in the pivotal trial to

Dupixent in the extension trial demonstrated improvement of 8.71 percentage points in lung function at two weeks.

The safety results of the trial were generally consistent with the known safety profile of Dupixent in its approved respiratory indications. Over the 52-week treatment period, the overall rates of adverse events (AEs) were 61-68%. The most common AEs (≥5%) were nasopharyngitis (9-10%), pharyngitis (6-10%), upper respiratory tract infection (4-8%), influenza (5-6%), eosinophilia (3-6%), allergic rhinitis (3-7%), diarrhea (4-6%) and injection site reactions (3-7%).

IRELAND’S LEADING FITNESS AND WELLNESS EXPERT, KARL HENRY TO BRING AN EXTRA BOOST TO PHARMATON WITH NEW PARTNERSHIP

The newest face of Pharmaton is leading fitness and wellness expert, and Podcast host Karl Henry. From tv screen stardom to bestselling author, no personal trainer in Ireland has a larger wheelhouse than Karl Henry. For the past decade he has led the charge in changing the wellbeing and lifestyle of the Irish public through his columns, guides, and television cameos. Karl will be involved in promoting Pharmaton’s latest immunity supplement, Immuno10; built to boost immunity and help you get back to living better faster.

Karl Henry’s voice and image will be taking over the health and fitness market as the face of Pharmaton with the campaign running from September 1st for two months across outdoor, radio, online and national print with an investment in excess of ¤250,000. The campaign itself will include in-store support in the form of window materials, floor stands and counter display units. Pharmaton is a leading multivitamin pharmacy-only brand that has been available in the Irish market for the last 20 years. Widely recommended by pharmacists, the range is high in vitamins and minerals designed to support energy, vitality and immunity. Personal Trainer and fitness expert Karl Henry was recently announced as brand ambassador.

Olivia Reilly, Marketing Manager Consumer Healthcare (Sanofi) said: “We are thrilled to have Karl on board to increase awareness around the importance of multivitamins in increasing health and wellbeing. There has been a great response from pharmacies excited to have Pharmaton on their shelves after months spent inside without any exposure to sickness, immune systems have let their guard down. Immuno10 was created to tackle this problem and bring our immunity back to and beyond its previous performance level. This product is made for the fast-paced modern life, boosting both our mental and physical endurance so we can get back to living faster and better.”

• Immune System: High in

Vitamins A, C and B Complex (B6, B9, B12) plus minerals Iron,

Zinc, Copper and Selenium, that each contribute to the normal function of the immune system – ideal as we approach the Cold /

Flu season.

• Vitality: Iron and magnesium are known to reduce fatigue and tiredness whilst Vitamin B complex (B1, B2, B3, B6) and Biotin all contribute to energy yielding metabolism which we need for all functions and activities of the body including exercise.

• Mental Performance: Vitamin

B5 contributes to normal mental performance – the tricky balancing act of hectic daily schedules needs all the support it can get! Pharmaton is available over the counter from almost all pharmacies nationwide (RRP: ¤17.95). The recommended daily dose is one film-coated tablet per day in the morning with a glass of water, preferably at breakfast. Immuno10 is suitable for adults 18 years +. Food supplements should not replace a balanced diet or healthy lifestyle. Always read the label.

BOOTS IRELAND LAUNCHES THIS YEAR’S BOOTS NIGHT WALK IN AID OF THE IRISH CANCER SOCIETY

Boots Ireland has partnered with TV presenter and broadcaster Darren Kennedy, to launch this year’s Boots Night Walk in aid of the Irish Cancer Society Night Nursing service which provides end-of-life care for people living with cancer in Ireland. The Irish Cancer Society Night Nursing service provides up to 10 nights of care, free to people who avail of it, and it is funded almost entirely by donations. Boots Ireland has partnered with the Irish Cancer Society since 2012 and through the support of their Team Members, patients and customers have raised ¤2.5 million for the service so far, helping to provide 7,200 nights of care. This year, the Boots Night Walk is back in person and hopes to be the biggest one yet, with Boots Ireland calling upon the public to sign up and walk 5km together this autumn in support of the Irish Cancer Society Night Nurses. Alongside the walk, Honour Tags are now on sale in Boots stores nationwide for ¤2. Customers can purchase a tag in honour of someone who has survived or passed away from cancer. The front of the tag allows for the name of the individual with space on the back for a personal message. One metre will be walked in honour of that person by members of the Boots Ireland team.

All funds raised from the Boots Night Walk will go towards the Irish Cancer Society Night Nursing service which provides end-of-life care for cancer patients, allowing them to spend their final days at home surrounded by family and loved ones, as well as giving much needed respite for the family caring for them. Managing Director at Boots Ireland, Stephen Watkins, said, “This year the Boots Night Walk is back in person and hopes to be the biggest one yet The Boots Night Walk helps to raise funds and awareness of the incredible work these Night Nurses undertake. Over the past 10 years an incredible ¤2.5 million has been raised for this service so we want to say a big thank you from Boots Ireland to the public as this cannot be done without your fundraising and support.”

Boots Night Walks Campaign ambassador TV Presenter and Broadcaster Darren Kennedy, launches the Boots Night Walks in aid of the Irish Cancer Society Night Nursing service